144 related articles for article (PubMed ID: 8540726)
21. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.
Rastogi N; Goh KS; Bryskier A; Devallois A
Antimicrob Agents Chemother; 1996 Jul; 40(7):1610-6. PubMed ID: 8807049
[TBL] [Abstract][Full Text] [Related]
22. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
McDermott-Lancaster RD; Banerjee DK
Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Sato K; Akaki T; Tomioka H
J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis.
Chiodini RJ
J Antimicrob Chemother; 1991 Feb; 27(2):171-6. PubMed ID: 1647388
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Visalli MA; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
[TBL] [Abstract][Full Text] [Related]
26. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
27. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.
Eliopoulos GM; Wennersten CB; Moellering RC
Diagn Microbiol Infect Dis; 1996 May; 25(1):35-41. PubMed ID: 8831043
[TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.
Klugman KP; Capper T; Bryskier A
Antimicrob Agents Chemother; 1996 Dec; 40(12):2802-4. PubMed ID: 9124844
[TBL] [Abstract][Full Text] [Related]
30. In vitro activities of 2,2'-bipyridyl analogs against Mycobacterium leprae.
Dhople AM; Ibanez MA; Dhople AA
Antimicrob Agents Chemother; 1994 Dec; 38(12):2908-9. PubMed ID: 7695282
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
Herbert D; Paramasivan CN; Venkatesan P; Kubendiran G; Prabhakar R; Mitchison DA
Antimicrob Agents Chemother; 1996 Oct; 40(10):2296-9. PubMed ID: 8891133
[TBL] [Abstract][Full Text] [Related]
33. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
34. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
35. Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.
Patel JA; Pachucki CT; Lentino JR
Antimicrob Agents Chemother; 1993 Feb; 37(2):339-41. PubMed ID: 8452367
[TBL] [Abstract][Full Text] [Related]
36. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.
Bebear CM; Renaudin H; Bryskier A; Bebear C
Antimicrob Agents Chemother; 2000 Jul; 44(7):1980-2. PubMed ID: 10858366
[TBL] [Abstract][Full Text] [Related]
37. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
Pattyn SR; Hébrant F
Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
Gómez-Lus R; Adrián F; del Campo R; Gómez-Lus P; Sánchez S; García C; Rubio MC
Int J Antimicrob Agents; 2001 Jul; 18(1):49-54. PubMed ID: 11463526
[TBL] [Abstract][Full Text] [Related]
39. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).
Saito H; Sato K; Tomioka H; Dekio S
Tuber Lung Dis; 1995 Oct; 76(5):377-80. PubMed ID: 7495996
[TBL] [Abstract][Full Text] [Related]
40. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.
Baltch AL; Smith RP; Franke MA; Michelsen PB
Antimicrob Agents Chemother; 1998 Dec; 42(12):3153-6. PubMed ID: 9835507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
